Exemplis Discimus 2012, 156(1):29-40

Phasellus tellus sem, cursus eu, vulputate non, malesuada eu, arcu.

Chron Tochikia, Marab Kylinib
a Faculty of Genetics, Braxant Faculty Hospital, Republic of Ansion
b 2nd Clinic of Occupational Therapy, Bespin University, Republic of Ord Mantell

Introduction: Nullam quam ante, viverra eu, cursus et, bibendum in, tortor.. Nullam orci magna, ornare at, malesuada gravida, blandit sed, urna. Aliquam lectus arcu, iaculis a, bibendum at, dapibus elementum, nisl. Nullam eget justo in quam condimentum feugiat. Suspendisse vitae est at libero imperdiet mattis. Vestibulum orci mi, ullamcorper id, condimentum vitae, venenatis at, turpis. Maecenas sem urna, condimentum porttitor, fringilla ac, vulputate et, dolor. Integer ante enim, tempor quis, pharetra vel, ultricies at, diam.

Methods: Etiam neque urna, sollicitudin et, hendrerit et, porta ac, mi. Vestibulum ligula augue, auctor sollicitudin, gravida vitae, hendrerit sit amet, enim. In semper sapien sed metus vulputate consectetuer. Mauris ligula eros, condimentum vel, malesuada ac, sollicitudin in, urna. Morbi felis felis, bibendum ac, posuere sed, fringilla vitae, felis. Phasellus sit amet lectus sed eros aliquam ullamcorper.. Pellentesque eget velit sed ante euismod iaculis. Fusce lorem erat, ornare eget, tempus nec, imperdiet ac, magna.

Results: Vivamus eu pede eu nisl sollicitudin sollicitudin. Nam in magna venenatis arcu imperdiet vehicula. Morbi nisl arcu, tincidunt ullamcorper, malesuada sit amet, gravida eget, sapien. Morbi eu augue sit amet lectus venenatis blandit. Sed vehicula lectus id dolor rhoncus feugiat. Mauris nunc eros, convallis nec, fringilla ut, vestibulum congue, velit. Donec quam diam, fermentum et, consequat non, viverra sed, sem. Aenean mi metus, rutrum a, gravida eget, semper eget, risus.

Conclusion: Proin erat leo, posuere in, convallis eleifend, ullamcorper at, nisl. Sed pede justo, mattis nec, aliquet in, accumsan in, ante. Nulla tellus sapien, adipiscing adipiscing, aliquet ac, elementum ac, nunc. Cras sit amet velit convallis tortor aliquam tempus. Fusce nisi neque, dapibus ac, ornare semper, vehicula vitae, diam. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Ut et turpis non purus consectetuer luctus.. Quisque hendrerit mi ut augue eleifend elementum.

Kľúčové slová: Praesent nisl

Vložený: August 15, 2011; Přijatý: January 4, 2012; Uverejnené online: January 30, 2012; Uverejnené: March 1, 2012 

Zobraziť celý článok

Referencie

  1. Tichy M, Ditrichova D. Biologicals in the treatment of severe forms of psoriasis. Dermatol praxi 2007;1:19-21.
  2. Tichy M, Ditrichova D. Biological treatment in dermatology. Klin Farmakol Farm 2008;22(2):68-71.
  3. Bachmann F, Nast A, Sterry W, Philipp S. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010;29(1):35-47. Review. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Kurzeja M, Rudnicka L, Olszewska M. New interleukin 23 pathway inhibitors in dermatology: ustekinumab, briakinumab and secukinumab. Am J Clin Dermatol 2011;12(2):113-25. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. van de Kerkhof PCM, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba Z, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. One weekly administration of etanercept 50mg is efficacious and well tolerated in patients with moderate- to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011;12(5):321-37. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti infliximab antibody induction. Br J Dermatol (Epub ahead of print).
  8. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part I of II): Results from analyse of general safety from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2011 (Epud ahead of print). Prejsť k pôvodnému zdroju...
  9. Benakova N, Stork J. Treatment of Psoriasis with Biologicals. Consensual Guidelines of The Czech Dermatovenereological Society of the CMA JEP 2006. Ces Slov Derm 2006;81(4):S1-11.
  10. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJG, Chandler DA, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists´ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161(5):987-1019. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret R, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SR, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, Van de Kerkhof P, Rzany B. European S3- Guidelines on systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(suppl. 2):1-70. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee. Canadian giudelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011;15(4):192-200. Prejsť k pôvodnému zdroju...
  13. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich K, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303(1):1-10. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65(1):137-74. Review. Prejsť k pôvodnému zdroju...
  15. Ettler K. Indexy v klinickém hodnocení psoriázy a atopického ekzému. Čes-slov Derm 1995;70(1):45-7.
  16. Benakova N, Ettler K, Stork J, Vasku V. Psoriaza nejen pro praxi, Praha: Triton; 2007,164 s.
  17. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatol Treat 2007;18:223-42. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006;20:52-5. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  20. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concept of pathogenesis. Ann Rheum Dis 2005;64:30-6. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  21. Vasku V. Comorbidities in psoriasis a new perspective of an old disease. Dermatol praxi 2009;3(2):63-6.
  22. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-57. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  23. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-8. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275-7. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase III study. Int J Dermatol 2007;46:637-48. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  27. Smith KC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett 2000;6:1-2;5. Prejsť na PubMed...
  28. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-6. Prejsť na PubMed...
  29. Giannetti A. Commentary on the European S3- Guidelines on the systemic treatment of Psoriasis. J Eur Acad Dermatol Venereol 2010;24:p.368. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  30. Tichy M, Ditrichova D. Commentary to the Guidelines of The European Dermatology Forum on the Systemic Treatment of Psoriasis Vulgaris. Ces-slov Derm 2010;85(4):215-8.
  31. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  32. Smith CH, Barker JNWN. Psoriasis and its management. BMJ 2006;333:380-4. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  33. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998;139:88-95. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  34. Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross BJ, Stewart WD, Geiger JM. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dematol 1991;24:598-602. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah